Cargando…

Correction: Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer

Detalles Bibliográficos
Autores principales:	Gao, Mei, Lin, Miranda, Moffitt, Richard A., Salazar, Marcela A., Park, Jinha, Vacirca, Jeffrey, Huang, Chuan, Shroyer, Kenneth R., Choi, Minsig, Georgakis, Georgios V., Sasson, Aaron R., Talamini, Mark A., Kim, Joseph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403294/ https://www.ncbi.nlm.nih.gov/pubmed/32393850 http://dx.doi.org/10.1038/s41416-020-0879-6

Ejemplares similares

Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer
por: Gao, Mei, et al.
Publicado: (2018)

Comparative single-cell RNA sequencing (scRNA-seq) reveals liver metastasis–specific targets in a patient with small intestinal neuroendocrine cancer
por: Rao, Manisha, et al.
Publicado: (2020)

Coordinated single-cell tumor microenvironment dynamics reinforce pancreatic cancer subtype
por: Oh, Ki, et al.
Publicado: (2023)

Case report of intestinal non-rotation, heterotaxy, and polysplenia in a patient with pancreatic cancer
por: Pagkratis, Spyridon, et al.
Publicado: (2017)

Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer
por: Roa-Peña, Lucia, et al.
Publicado: (2019)

Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer
por: Al-Hajeili, Marwan, et al.
Publicado: (2014)

Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives
por: Woo, Wonhee, et al.
Publicado: (2019)

Current Landscape and Future Direction of PD-1/PD-L1 Checkpoint Inhibitors in Cancer Treatment
por: Serratì, Simona, et al.
Publicado: (2023)

Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic cancer cells
por: Harper, Megan M., et al.
Publicado: (2022)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
por: Koopmans, Iris, et al.
Publicado: (2018)

Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer
por: Zhang, Yaqing, et al.
Publicado: (2017)

From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation
por: Mouw, Kent W., et al.
Publicado: (2018)

Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer
por: Yang, Ching-Yao, et al.
Publicado: (2020)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma
por: Daunke, Tina, et al.
Publicado: (2023)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
por: Pesce, Silvia, et al.
Publicado: (2019)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
por: Hashimoto, Kazuhiko, et al.
Publicado: (2020)

Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
por: Anand, Kartik, et al.
Publicado: (2020)

Targeting YAP/TAZ in Combination with PD-L1 Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC)
por: Papavassiliou, Kostas A., et al.
Publicado: (2023)

Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer
por: Messeha, Samia S., et al.
Publicado: (2021)

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
por: Kleinovink, Jan Willem, et al.
Publicado: (2017)

Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition
por: Hassel, Jessica C., et al.
Publicado: (2023)

Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis
por: Zyla, Edyta, et al.
Publicado: (2021)

MicroRNA-519 inhibits hypoxia-induced tumorigenesis of pancreatic cancer by regulating immune checkpoint PD-L1
por: Nong, Kate, et al.
Publicado: (2020)

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
por: Ilcus, Cristina, et al.
Publicado: (2017)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
por: Sharma, Meenal, et al.
Publicado: (2019)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint
por: Konieczny, Magdalena, et al.
Publicado: (2020)

PD-1 Checkpoint Inhibitor Associated Autoimmune Encephalitis
por: Schneider, Stephanie, et al.
Publicado: (2017)

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
por: Ziogas, Dimitrios C., et al.
Publicado: (2023)

PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression
por: Filippone, A., et al.
Publicado: (2022)

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
por: Skalniak, Lukasz, et al.
Publicado: (2017)

Anti-PD-1 checkpoint blockade monotherapy in the orthotopic GL261 glioma model: the devil is in the detail
por: Tritz, Zachariah P, et al.
Publicado: (2021)

The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
por: Wang, Qingshui, et al.
Publicado: (2017)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
por: Wang, Dongxu, et al.
Publicado: (2019)

Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas
por: Hashimoto, Kazuhiko, et al.
Publicado: (2021)

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
por: Tang, Qing, et al.
Publicado: (2022)

Clinicopathological assessment of PD-1/PD-L1 immune checkpoint expression in desmoid tumors
por: Hashimoto, Kazuhiko, et al.
Publicado: (2023)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
por: Gu, Tingxuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ees1c16bjcgcua1nqliv28o9pv